D.E. Shaw & Co
MLYS icon

D.E. Shaw & Co’s Mineralys Therapeutics MLYS Stock Holding History

D.E. Shaw & Co’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24M Sell
887,192
-263,478
-23% -$7.73M 0.01% 1034
2025
Q4 		$41.8M Buy
1,150,670
+539,747
+88% +$21.6M 0.02% 805
2025
Q3 		$23.2M Buy
610,923
+36,716
+6% +$794K 0.01% 1082
2025
Q2 		$7.77M Buy
574,207
+95,777
+20% +$1.39M 0.01% 1693
2025
Q1 		$7.6M Buy
+478,430
New +$5.5M 0.01% 1595

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

D.E. Shaw & Co's MLYS Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Mineralys Therapeutics (MLYS) stake by 23% in Q1 2026, selling an estimated $7.73M and leaving 887,192 shares worth $24M. The position accounts for 0.01% of the portfolio, ranked #1034.

D.E. Shaw & Co first reported a position in MLYS in Q1 2025 and has held it in 5 quarters since. The position peaked at $41.8M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • D.E. Shaw & Co held 887,192 shares of Mineralys Therapeutics worth $24M as of Q1 2026.
  • D.E. Shaw & Co sold 263,478 Mineralys Therapeutics shares in Q1 2026, an estimated $7.73M.
  • Mineralys Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1034 holding.
  • D.E. Shaw & Co first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • D.E. Shaw & Co's Mineralys Therapeutics position peaked at $41.8M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.